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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.002Breast cancer is a complex disease characterized bymanymorphological, clinical, andmolecular features. For
many years, breast cancer has been classiﬁed according to traditional parameters, such as histological type,
grade, tumor size, lymph node involvement and vascular invasion, and biomarkers (eg, estrogen receptor,
progesterone receptor, andepidermal growth factor receptor 2),which areused inpatientmanagement.With
emerging imaging techniques (ie, digital mammography, tomosynthesis, ultrasonography, magnetic reso-
nance imaging, nuclear medicine, and genomic techniques, such as real-time RT-PCR and microarrays),
breast cancer diagnostics is going through a signiﬁcant evolution. Imaging technologies have improved
breast cancer diagnosis, survival, and treatment by early detection of primary or metastatic lesions,
differentiating benign from malignant lesions and promoting intraoperative surgical guidance and post-
operative specimen evaluation. Genomic and transcriptomic technologies make the analysis of gene
expression signatures and mutation status possible so that tumors may be classiﬁed more accurately with
respect todiagnosis andprognosis. The -omic era has alsomadepossible the identiﬁcationof newbiomarkers
involved in breast cancer development, survival, and invasion that can be gradually incorporated into clinical
testing. These advances in both imaging and genomics contribute to more personalized and predictive
patient management. We review the progress made in breast cancer diagnosis and management using these
new tools. (Am J Pathol 2013, 183: 1075e1083; http://dx.doi.org/10.1016/j.ajpath.2013.07.002)Supported in part through the Department of Pathology Translational
Research Shared Resource Laboratory of the Geisel School of Medicine at
Dartmouth, NH, the Dartmouth Hitchcock Medical Center, and the Norris
Cotton Cancer Center.
This article is part of a review series on the molecular pathogenesis of
breast cancer.For many years, breast cancer has been classiﬁed according to
clinical andpathological criteria (ie, histological features, grade,
tumor size, lymph node involvement, and vascular invasion)
(Figure 1). However, the predictive power of these criteria for
selection of the optimal therapeutic approach is limited.
In the past decade, signiﬁcant advances in genomic and
proteomic technologies have allowed researchers to better
understand tumor cell biological characteristics and identify
biological biomarkers involved in multiple signaling path-
ways that can improve general clinical practice [ie, early
detection, determination of clinical outcomes (prognosis),
diagnosis, detection of recurrence after therapy, risk
assessment, identiﬁcation of targets for therapy, prediction
of response to therapies (prediction), monitoring clinical
outcomes of therapies, and imaging disease processes].1
Rapid technological developments, such as real-time RT-
PCR and microarrays, have allowed testing of numerous
biomarkers and a more detailed classiﬁcation of breaststigative Pathology.
.cancer, contributing to a personalized prognostic and pre-
dictive approach to management.2
Imaging techniques have also improved signiﬁcantly
during the past few years. According toGrizzle et al,1 imaging
can detect primary or metastatic lesions and differentiate
benign from malignant lesions. The necessity of novel
biomedical imaging methods is to increase the frequency and
accuracy with which disease can be detected and also to
improve the prediction and monitoring of its progression or
regression during treatment.3
Because signiﬁcant technological progress has helped to
individualize the diagnosis and treatment of breast cancer,4
Figure 1 Histological subtypes of breast carcinoma (H&E stain). A: Invasive ductal breast cancer. B: Invasive lobular breast cancer. C: Tubular breast
cancer. D: Medullary breast cancer. E: Mucinous breast cancer. Original magniﬁcations: 20 (A, C, and E); 10 (B); 40 (D).
De Abreu et althis review will provide an overview of the following: i) the
latest developments in breast imaging and its importance for
screening; ii) the markers clinically used for diagnosis,
prognosis, and treatment; iii) the molecular subtypes of
breast cancer; iv) the commercially available molecular
signatures for predicting outcomes; and v) the importance of
new biomarkers identiﬁed by array comparative genomic
hybridization and next-generation sequencing.
Screening/Diagnostics
Imaging techniques (ie, digital mammography, tomosyn-
thesis, ultrasonography, magnetic resonance imaging, and
nuclear medicine) have improved breast cancer screening
and show promise for intraoperative surgical guidance and
postoperative specimen evaluation.
Mammography is considered the gold standard method of
early breast cancer detection and diagnosis, but it has limita-
tions, such as low sensitivity in dense breasts (Figure 2A). To
improve mammographic sensitivity, complimentary imaging
modalities, including digital breast tomosynthesis mammog-
raphy (DBT) and contrast-enhanced digital mammography
(CEDM), ultrasound, andmagnetic resonance imaging (MRI),
are often recommended. DBT is the basic mammography
technique modiﬁed to capture multiple views of the breast at
different angles and generate a three-dimensional (3D) image
of the breast (Figure 2, CeF). According to Kilburn-Toppin
and Barter,5 DBT has a high sensitivity and has been shown
to improve lesion characterization, especially in women with
dense breasts. DBT alone or in combination with CEDM
results in a signiﬁcant improvement in sensitivity. The CEDM1076technique uses the combination of an iodinated contrast agent
with a mammography examination.5,6 It also has a high
sensitivity and a better diagnostic accuracy than mammog-
raphy alone and mammography with ultrasound.7,8
Ultrasound imaging is used to detect, characterize, and
guide biopsy of breast lesions (Figure 2B). For clinical
examination, ultrasound screening is performed in combina-
tion with mammography. Because this technique also has
some limitations (ie, inability to identify characteristics of
benign and malignant lesions and inability to identify cancer
in women with dense breasts), many modiﬁcations of this
technique are being developed, such as 3D ultrasound, auto-
mated ultrasound,Doppler ultrasound, and sonoelastography.
Both mammography and ultrasound imaging alone are
able to distinguish benign from malignant pathological
conditions, with sensitivity values of 60.9% and 95.7%, and
negative predictive values of 99.2% and 99.9%, respectively.
Recently, computer-aided detection or diagnostic (CAD)
systems have been developed to help radiologists increase
diagnostic accuracy, using either mammography or ultra-
sound.9 Computer-aided detection systems, CADe, were
designed to assist radiologists in detecting and locating
abnormal areas in images, and computer-aided diagnostic
systems, CADx, were designed to diagnose and classify
benign from malignant tissues. In mammography, these
automated systems are classiﬁed into two groups: CADe,
which generates a mammogram image with the abnormali-
ties, and CADx, which helps the radiologist to grade them
as benign or malignant. With ultrasound, CAD encompasses
four stages: i) image processing, ii) image segmentation, iii)
feature extraction and selection, and iv) classiﬁcation.ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Imaging techniques for breast cancer
screening and diagnosis. A: Mammography image
of an irregular density (red arrow) breast cancer
that exactly correlates with the excised invasive
breast cancer (red arrow, inset) surrounded by
fat. B: Ultrasound imaging. Hypoechoic, irregularly
outlined invasive breast cancer (red arrows) with
increased vascularity (asterisk). CeF: Tomosyn-
thesis imaging. C: Two-dimensional (2D) FFDM
craniocaudal (CC) view shows a questionable focal
asymmetry with architectural distortion. D: 3D
tomoframe CC view. E: 2D mediolateral oblique
(MLO) view is negative. F: MLO views demonstrate
an irregular mass with distortion and spiculations
consistent with cancer. FFDM, full-ﬁeld digital
mammography. G and H: PET-CT imaging. Regis-
tered PET-FDG (G) and CT (H) scans show a right,
1.5-cm hypermetabolic breast cancer (red arrows),
close to the chest wall. L, left; R, right.
Breast Cancer Molecular DiagnosticsMRI is effective for screening dense breasts, and by
identifying additional occult lesions in the ipsilateral or
contralateral breast, it can help determine whether lumpec-
tomy or mastectomy (unilateral or bilateral) is the best
treatment option. To locate the tumors, this technique
requires the use of an intravenous contrast agent that high-
lights areas with dense vessel linkages, leading to many false
positives. Thus, although MRI has a high sensitivity (94% to
100%), the speciﬁcity is low (37% to 97%).10 Lee et al11
suggested that the combination of MRI and mammography
for screening might improve the chances of detecting early-
stage cancers. However, MRI is not used routinely for
screening.
Nuclear medicine has been used in oncological imaging for
diagnosis, treatment decision, or treatment response moni-
toring. Positron emission tomography (PET) is a nuclear
medicine screening technique that consists of the injection
of radiolabeled ligands into the patient. PET produces 3DThe American Journal of Pathology - ajp.amjpathol.orgimages based on the detection of altered physiological char-
acteristics, rather than anatomical characteristics. Malignant
cells frequently have increased glucosemetabolism compared
with normal cells. The radiolabeled ligands attach to glucose
molecules, producing a contrast between cancerous and
normal cells in PET images, providing information about the
chemical functions inside organs and tissues.4,6 Computed
tomography (CT) screening uses iodinated contrast intrave-
nously to increase the contrast of the CT images to provide
anatomical information. The PET-CT technique combines the
advantage of PET, which indicates the metabolic activity of
the malignant cells (based on glucose level), and CT, which
identiﬁes their location (Figure 2, G and H).6 The PET-CT
procedure is able to distinguish benign from malignant
breast tumors, and it also detects axillary metastases, with
a sensitivity and speciﬁcity of 73% and 100%, respectively.
Although imaging techniques are improving the overall
sensitivity and speciﬁcity of breast cancer screening and1077
Figure 3 IHC (AeC) and FISH (D) analyses of breast cancer. A: ERþ
strong intensity. B: PRþ moderate intensity. C: HER-2 overexpression, score
3þ. D: HER-2 gene ampliﬁcation. Original magniﬁcation: 20 (A and B).
De Abreu et aldiagnosis, they are mostly effective at indicating the loca-
tion of the tumor within the breast. Some of them can often
act as guides to disease extent, but the surgeon must still
estimate the extent of disease, which may correlate with an
increased risk of local recurrence and decreased survival.
Therefore, techniques for real-time intraoperative surgical
guidance and postoperative specimen evaluation are being
developed and tested to improve the accuracy of surgical
excision, reduce the recurrence rate, and increase the sur-
vival percentage.
Laughney et al12 developed a new spectroscopic imaging
technique to detect and distinguish microscopic pathological
features in resected breast tissues. This scatter spectroscopic
imaging technique differentiates benign from malignant
pathological conditions with 94% accuracy in surgical
tissues and identiﬁes new imaging signatures, such as
texture (correlation, contrast, and homogeneity) and shape
(fractal dimension and Euler number) features to discrimi-
nate benign from malignant pathological conditions.
Prognostic and Predictive Biomarkers
Several biomarkers have been identiﬁed by high-throughput
technologies, but only hormone receptors, such as estrogen
(ER), progesterone (PR), and human epidermal growth
factor receptor 2 (HER2), are routinely used clinically for
breast cancer prognosis and therapeutic purposes (Figure 3).
Estrogen Receptor
Estrogen receptor, a member of the nuclear transcription
receptor superfamily, is activated by steroid hormones, such as
estrogen. Estrogen and its receptors are involved in several
processes, including cellular proliferation, inhibition of
apoptosis, invasion, and angiogenesis.13 ER has two isoforms,
ER-a and ER-b, both expressed in the normal mammary
gland; ER-a is directly involved in pathological processes,
including breast cancer. Estrogen receptor expression is1078considered one of the most important biomarkers in breast
cancer and a positive target for anti-estrogen therapy.
Because estrogen inhibition can increase early breast
cancer cure rates, improve the response rate in advanced
disease, and reduce breast cancer incidence, ER-positive
patients beneﬁt from endocrine therapy,whereas ER-negative
tumors do not. Tamoxifen is a selective modulator of ER that
blocks steroidmechanisms preventing cellular replication and
proliferation. The Early Breast Cancer Trialists’ Collabora-
tive Group14 reported that ER patients treated with tamoxifen
had little effect on recurrence or breast cancer mortality in 5
years. Several studies have shown that 21% to 33% of ER-
negative patients treated with neoadjuvant chemotherapy
achieve a pathologically complete response, whereas only 7%
to 8% of ER-positive patients achieved it.15,16
Recently, some studies were performed to verify if there
was differential beneﬁt from aromatase inhibitors (AIs) and
tamoxifen in different subgroups of breast cancer. Anas-
trozole, tamoxifen, alone or in combination (ATAC),17 and
breast international group 1-98 (letrozole versus tamox-
ifen)18 trials showed that ER status did not lend a greater
beneﬁt from either AIs or tamoxifen.
Progesterone Receptor
The PR gene is an estrogen-regulated gene. Its expression
depends on the presence of ER; thus, it is rarely seen in ER-
negative tumors. Approximately half of the ER-positive
tumors express PR.13 Although PR-negative patients have
a worse outcome than PR-positive patients treated with
tamoxifen, the relativebeneﬁt of this treatment is similar inboth
groups.17 In 2005, Dowsett et al19 (the ATAC trial on PR-
negative and PR-positive patients) showed that the ﬁrst group
had greater beneﬁt from anastrozole than tamoxifen. However,
the breast international group 1-98 trial, performed by Viale
et al,18 demonstrated that PR status did not affect outcomes
with either AI or tamoxifen treatment.
HER2
HER2 belongs to the human epidermal growth factor receptor
family of tyrosine kinases, which includes epidermal growth
factor receptor (EGFR; HER1), HER3, and HER4. HER2 can
regulate cell proliferation, survival, and other processes
important for carcinogenesis. The activation of HER2, which
occurs through gene ampliﬁcation, leading to receptor protein
overexpression, is identiﬁed in 15% to 20% of all breast
cancers. This overexpression makes it a robust target for and
predictor of the beneﬁt from treatment with trastuzumab
(Herceptin; Genetech, South San Francisco, CA). Trastuzu-
mab is a monoclonal antibody that targets the extracellular
domain of the HER2 receptor, blocking its activation.
Several technologies, such as immunohistochemistry
(IHC), ﬂuorescence in situ hybridization (FISH), real-time
RT-PCR, and enzyme-linked immunosorbent assay, are
able to detect HER2 status, but only IHC and FISH haveajp.amjpathol.org - The American Journal of Pathology
Breast Cancer Molecular Diagnosticsbeen clinically used to detect HER2 gene ampliﬁcation and/
or overexpression20 in a routine clinical setting.
IHC is a semiquantitative method that detects HER2
receptor expression on the cell surface using a grading system
(0, absence; 1þ, negative; 2þ, equivocal; 3þ, overex-
pression). Although this is the most routinely used method to
detect HER2 status, it has some disadvantages (different
ﬁxation protocols, scoring systems, and antibody selection),
which compromise its reproducibility and accuracy. FISH is
a quantitative method that measures gene copy number. It is
more reproducible and accurate when compared with IHC.
To obtain more accurate results, the American Society of
Clinical Oncology and the College of American Pathologists
published a guideline with recommendations for HER2
evaluation.13Molecular Proﬁle of Breast Cancer
Transcriptional proﬁling technologies (ie, gene expression
microarrays) analyze the expression of thousands of genes
simultaneously, allowing for a tumor molecular proﬁle
design. According to the literature, a quantitative study of
multiple genes provides more accurate information about
the molecular proﬁle of the tumor than a conventional single
marker.21,22
Perou et al23 published the ﬁrst article classifying breast
cancer into intrinsic or molecular subtypes based on gene
expression patterns using hierarchical clustering, which
groups genes and samples according to similarity in their
patterns of gene expression. This study classiﬁed breast can-
cer into four molecular subtypes: luminal, HER2 enriched,
basal-like, and normal breast-like. In 2006, an expansion of
this study in a larger group of patients showed that the luminal
group could be divided into two categories, luminal A
and luminal B.24 Furthermore, in 2007, the same group of
researchers reported a new molecular subtype, claudin-low.25Table 1 Summary of Characteristics of Molecular Subtypes
Molecular subtype Luminal A Luminal B
Frequency (%) 50-60 10-20
Genetic expression
proﬁle
ER-related genes,
Yproliferation genes
[Proliferation genes
Histological grade Low High
IHC markers ERþ, PRþ, HER2, Ki-67,
CK8/18þ, GATA3þ
ERþ, PRþ/, HER2þ/,
EGFRþ, [Ki-67
Prognosis Good Intermediate/poor
Response to
chemotherapy
Low (7% CR) Intermediate (17% CR)
Treatment AI and SERMs: tamoxifen Tamoxifen and AI
New treatment
targets
PI3K/AKT/mTOR pathway PI3K/AKT/mTOR
pathway
CAV, caveolin; CK, cytokine; CR, complete response; GATA, GATA binding pro
homolog; SERM, selective estrogen receptor modulator.
The American Journal of Pathology - ajp.amjpathol.orgRecently, the mRNA expression subtypes, known as
luminal A, luminal B, HER2, and basal-like, were analyzed
using different platforms, including genomic DNA copy
number arrays, DNA methylation, exome sequencing,
mRNA arrays, miRNA sequencing, and reverse-phase
protein arrays.26 This study evaluated individual platforms
and integrated pathways identifying several subtype-speciﬁc
mutations and copy number changes that might be thera-
peutically targetable. Table 1 summarizes the characteristics
of the molecular subtypes.
Luminal
The luminal/ERþ breast cancers are the most heterogeneous
in terms of gene expression, mutation spectrum, copy
number changes, and patient outcomes.26 The main bio-
logical difference between luminal A and B subtypes is an
increased expression of proliferation genes and an expres-
sion of EGFR and HER2 identiﬁed in luminal B tumors.22
The luminal A subtype represents 50% to 60% of breast
cancer cases. Its IHC proﬁle is characterized by the
expression of ER, PR, CK8/18, GATA3, and TP53, low
expression of Ki-67, and absence of HER2 expression. This
subtype is characterized by low histological grade and good
prognosis. These tumors show a high frequency of PIK3CA
mutation (49%) and low TP53 mutation (12%).26 The
treatment of these patients is based on hormonal AIs in
postmenopausal women and/or selective estrogen receptor
modulators, such as tamoxifen.
The luminal B subtype represents 10% to 20% of all
breast cancers. Compared with the luminal A subtype, they
have a higher grade, worse prognosis, and worse prolifera-
tive index, leading to a more aggressive phenotype. These
tumors are ERþ, PRþ/, Her2þ/, and EGFRþ, and have
a high Ki-67. They also have a high frequency of PIK3CA
(32%) and TP53 (29%) mutations, ATM loss, and MDM2
ampliﬁcation.26 Although these patients have a worseHER2 positive Basal-like (or TNBC)
Claudin-low
(or TNBC)
15-20 10-20 12-14
HER2-related genes,
[proliferation genes
CKs, P-cadherin,
CAV1/2, CD44, KIT
YCell-cell junction
genes, [immune
response genes
High High High
ER, PR, HER2þ ER, PR, HER2,
EGFRþ, CK5/6þ
ER, PR, HER2
Poor Poor Poor
High (43% CR) High (36% CR) Low
HER2 target therapy PARP-1 inhibitors PARP-1 inhibitors
PI3K/AKT/mTOR
pathway
PI3K/AKT/mTOR and
RAS-RAF-MEK
pathway
tein; KIT, v-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene human
1079
De Abreu et alprognosis, 17% of them reach complete response when
treated with neoadjuvant chemotherapy.22 They respond to
either tamoxifen or AI.
Because luminal cancers have a high frequency of
PIK3CA mutations, patients may be able to beneﬁt from
investigational drugs in human clinical trials that inhibit
the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian
target of rapamycin (mTOR) pathway.
HER2 Enriched
This molecular subtype corresponds to 15% to 20% of all
breast cancers. Among them, only 60% are clinically HER2þ,
and the rest are luminal B>luminal A>basal-like.27 It is
characterized by overexpression of HER2- and HER2-
associated genes, a high proliferative index, a high his-
tological grade, a poor prognosis, and a high response to
neoadjuvant chemotherapy (43% partial cytogenetic re-
sponse). According to The Cancer Genome Atlas Network,26
HER2-positive tumors are divided into two subgroups: HER2
positive and luminal-HER2 positive. HER2-positive patients
also show higher expression of RTK genes (FGFR4, EGFR,
and HER2) and TP53, whereas luminal-HER2epositive
patients show higher expression of the luminal cluster genes,
such as GATA3 and ER. Approximately 30% to 40% of
HER2þ tumors are ERþ.27 Of HER2-positive tumors, 75%
have a TP53 mutation and 42% have a PIK3CA mutation.
Patients are treated with trastuzumab, an anti-HER2 drug, but
they can also beneﬁt from the new therapeutic inhibitory
molecules of the PI3K/AKT/mTOR pathway.
Basal-Like
The basal-like subtype represents 10% to 20% of breast
cancer cases. They are characterized by a high proliferative
index, a high histological grade, a poor prognosis, and a high
response to neoadjuvant chemotherapy (36% partial cyto-
genetic response). Their IHC proﬁle shows absence of ER,
PR, and HER2 expression, and high expression of EGFR and
CK5/6. Although they are clinically characterized as triple-
negative breast cancer (TNBC), only 50% to 75% of them
are basal-like.27 Basal-like tumors have a high frequency of
TP53mutations (84%), combined with loss of TP53 function
and loss of RB1.26 They have been associated with germ-line
mutations in BRCA1. According to Bosch et al,28 variations,
such as mutations and epigenetic mechanisms, decrease
BRCA1 gene function and predispose to the development of
basal-like tumors, the absence of ER expression, and worse
prognosis. Because most of the basal-like tumors are TNBC,
it is difﬁcult to identify the best therapeutic targets for these
patients. Approximately 20% of patients have germ-line and/
or somatic BRCA1 or BRCA2 variants, suggesting that they
might beneﬁt from poly-ADP ribose polymerase-1 (PARP1)
inhibitors. The inhibition of PARP1 in patients with defec-
tive DNA repair by BRCA1 contributes to the accumulation
of breaks in the double-stranded DNA and to cell death.221080Several new targets, such as inhibitory molecules of the
PI3K/AKT/mTOR and RAS-RAF-MEK pathway, might
beneﬁt this group. Eroles et al22 reported that basal-like
cancers had ampliﬁed PIK3CA, KRAS, BRAF, and EGFR
(49%, 32%, 30%, and 23%, respectively).
Claudin-Low
Claudin-low subtype tumors represent 12% to 14% of all
breast cancers. They are characterized by low expression of
cell-cell junction proteins, such as claudin-3, claudin-4,
claudin-7, and E-cadherin. This subtype shows overex-
pression of genes involved in immune response, indicating an
intense immune cell inﬁltration,27,29,30 and genes linked to
mesenchymal differentiation and epithelial-mesenchymal
transition.22,27 The IHC proﬁle of this group shows absence
of ER, PR, and HER2 expression, but approximately 20% of
the tumors are positive for hormone receptors; therefore, they
are not true TNBC.31 Claudin-low tumors have a high grade
and a poor prognosis, because there is no speciﬁc treatment
for these patients. According to Perou,27 patients with these
tumors might beneﬁt from PARP1 treatment, because they
also have alterations in BRCA1 pathways.
Normal Breast-Like
Normal breast-like tumors correspond to 5% to 10% of all
cases. They express genes present in the adipose tissue and
lack expression of ER, PR, HER2, EGFR, and CK5. This
tumor subtype has an intermediate prognosis and does not
respond to neoadjuvant chemotherapy. Some researchers
believe that normal breast-like tumor is a result of a tech-
nical artifact due to contamination of normal tissue.32
Molecular Signature for Prediction
Recently, gene expression assays, such as MamaPrint
(Agendia, Inc., Irvine, CA), Oncotype DX (Genomic Health,
Redwood, City, CA), and the Genomic Grade Index (GGI;
Affymetrix, Santa Clara, CA), have become commercially
available (Table 2). By using real-time PCR or microarray
technology, these platforms identify a prognostic gene
signature to predict response to therapy.
The MamaPrint test (approved by the US Food and Drug
Administration) was developed from a gene expression
proﬁling analysis known as the Amsterdam 70-gene proﬁle
or signature (Table 2).33 This group of researchers identiﬁed
a 70-gene prognostic signature using a microarray platform
in node-negative breast cancer patients younger than 55
years. This signature consisted of genes involved in the cell
cycle, invasion, metastasis, angiogenesis, and signal trans-
duction. The 70-gene prognostic signature was validated in
node-negative and node-positive tumors, as well as treated
and untreated patients, and proved to be a robust predictor for
distant metastatic-free survival, independent of adjuvant
treatment, tumor size, histological grade, and age.13 A secondajp.amjpathol.org - The American Journal of Pathology
Table 2 Molecular Breast Cancer Signature for Prediction
Molecular signature Mamaprint Oncotype DX GGI
No. of genes assessed 70 21 97
Tissue type Fresh frozen FFPE Fresh frozen
Application Predictive of distant metastatic-free
survival in node-negative and
node-positive patients
Predictive of chemotherapy
in node-negative and
ERþ patients
Predictive of treatment
in histological grade
2 patients
Technique Microarray RT-PCR Microarray
Reference van’t Veer et al33 Paik et al35 Sotiriou et al36
FFPE, formalin ﬁxed, parafﬁn embedded.
Breast Cancer Molecular Diagnosticsvalidation was performed in node-negative T1-2 breast
tumors not treated with chemotherapy and compared with
traditional clinical factors included in the Adjuvant! Online
software (https://www.adjuvantonline.com/index.jsp, regis-
tration required, last accessed August 5, 2013). The 70-gene
proﬁle showed better prediction of time to distant metastasis
and overall survival.34
Oncotype DX, a 21-gene recurrence score (RS) prog-
nostic indicator, predicts the probability of distant recur-
rence in node-negative patients treated with tamoxifen, and
in those with ERþ breast cancer (Table 2).35 The assay
identiﬁes expression of 21 genes (5 reference genes and 16
genes associated with breast cancer), selected from a set of
250 genes previously studied by the National Surgical
Adjuvant Breast and Bowel Project clinical studies. Real-
time RT-PCR in formalin-ﬁxed, parafﬁn-embedded
samples was performed to quantify the expression of the 21
genes and calculate the RS, which classiﬁed patients into
three groups: high, intermediate, and low risk. The 21-gene
recurrence score was validated in 675 ERþ, node-negative,
tamoxifen-treated patients from the National Surgical
Adjuvant Breast and Bowel Project showing that RS
correlated with distant recurrence, relapse-free interval, and
overall survival, independent of age and tumor size. Onco-
type DX testing also includes markers used routinely in
diagnoses, such as ER, PR, and HER2.
The GGI signature was developed to reclassify patients
with histological grade 2 tumors, which is informative for
clinical decision making. Sotiriou et al36 analyzed microarray
data from 189 invasive breast cancers and identiﬁed 97 genes
associated with histological grade, most of them involved in
cell cycle regulation and proliferation (Table 2). These genes
were differentially expressed between high- and low-grade
breast tumors. The intermediate-grade tumors showed an
expression pattern similar to either high- or low-grade cases.
The GGI may increase the accuracy of tumor grading and
improve treatment decisions.
Although MamaPrint is applicable to either hormone
receptorepositive or hormone receptorenegative and lymph
nodeepositive or lymph nodeenegative patients, Oncotype
DX and GGI tests have a limited scope. The 21-gene proﬁle
(Oncotype DX) was designed to predict distant recurrence
during a 10-year period and to predict the response to
chemotherapy of lymph nodeenegative and hormone-
positive tumor. Approximately 15% of patients with ER-The American Journal of Pathology - ajp.amjpathol.orgpositive and lymph nodeenegative disease, treated with
tamoxifen, have a 10-year distant recurrence chance.37 The
97-gene proﬁle (GGI) was designed to grade tumors more
accurately than the conventional histological grade, espe-
cially grade 2 tumors. Although the implementation of these
molecular signatures may improve the clinical management
of breast cancer patients, the cost of these tests is relatively
high, approximately $4000 for MamaPrint and $3500 for
Oncotype DX, when compared with the usual pathological
testing, such as IHC.2
A major issue in IHC is the accuracy for pre-analytic
factors (ie, duration of ﬁxation, type of processing, and type
and intensity of the antigen used) and postanalytic factors
(ie, slide scoring system) and the cutoffs used to determine
positive and negative results. For this reason, typical path-
ological testing has been compared with these types of
molecular signatures. Knauer et al38 identiﬁed that 80% of
tumors classiﬁed as grade 1 by conventional methods were
classiﬁed as low-risk prognosis by the MamaPrint test,
while 20% were shown to be high risk by MamaPrint. For
patients who were identiﬁed as grade 3, 88% were identiﬁed
as high risk by the 70-gene proﬁle and 12% showed low
risk. Intermediate grade showed approximately 55% low
and 45% high risk by MamaPrint.
Future Directions
Although transcriptomic analysis is a powerful tool to
analyze multiple genes involved in breast cancer develop-
ment and to identity new prognostic and prediction markers,
the development of more sophisticated technologies, such as
next-generation sequencing, epigenetics, proteomics, and
metabolomics, is still needed for the following: i) to provide
a better understanding of breast tumorigenesis, ii) to identify
new driver genetic and epigenetic genes, iii) to characterize
intratumor heterogeneity, iv) to identify mechanisms of
resistance to therapy, and v) to identify new biomarkers for
prognostics and prediction, resulting in better and more
accurate monitoring for breast cancer.39
Recently, miRNAs have been widely investigated because
of their potential role as both novel biomarkers and targets
for cancer therapy. It is known that miRNAs are involved
in several biological processes, such as cell cycle regula-
tion, cell growth, apoptosis, cell differentiation, and stress
response.40 Tang et al41 observed a link between altered1081
De Abreu et almiRNA and breast cancer development and metastasis, either
through the loss of tumor-suppressor miRNAs or the over-
expression of oncogenic miRNAs in breast cancer cells.
Conclusions
Advances in imaging methods for breast cancer screening
have increased the frequency and accuracy with which
breast cancer is detected. They have also improved the
prediction and monitoring of disease during treatment.
Rapid developments, using new molecular technologies,
have provided new information about the biological char-
acteristics of the tumor and led to a reclassiﬁcation of breast
cancer from a molecular standpoint. These genomic tech-
niques reveal new biomarkers involved in neoplastic
development, survival, and invasion that can be gradually
incorporated into clinical testing. Together, these advances,
in both imaging and genomics, have contributed to a more
personalized management of the breast cancer patient.
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